Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Richard Sam, Emory Ryan, Emily Daykin & Ellen Sidransky. (2021) Current and emerging pharmacotherapy for Gaucher disease in pediatric populations. Expert Opinion on Pharmacotherapy 22:11, pages 1489-1503.
Read now
Read now
Articles from other publishers (12)
Renuka Pudi Limgala, Vyacheslav Furtak, Margarita M. Ivanova, Erk Changsila, Floyd Wilks, Marie N. Fidelia‐Lambert, Ozlem Goker‐Alpan & Marjorie C. Gondré‐Lewis. (2021) Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants. JIMD Reports 59:1, pages 60-68.
Crossref
Crossref
Asmaa M. Zahran, Mervat A. M. Youssef, Engy Adel Shafik, Zeinab Albadry M. Zahran, Omnia El-Badawy, Amir M. Abo Elgheet & Khalid I. Elsayh. (2020) Downregulation of B regulatory cells and upregulation of T helper 1 cells in children with Gaucher disease undergoing enzyme replacement therapy. Immunologic Research 68:2, pages 73-80.
Crossref
Crossref
Renuka P. Limgala & Ozlem Goker-Alpan. (2020) Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease. Biomolecules 10:4, pages 526.
Crossref
Crossref
Rick Hamler, Nastry Brignol, Sean W. Clark, Sean Morrison, Leo B. Dungan, Hui H. Chang, Richie Khanna, Michelle Frascella, Kenneth J. Valenzano, Elfrida R. Benjamin & Robert E. Boyd. (2017) Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease. Analytical Chemistry 89:16, pages 8288-8295.
Crossref
Crossref
Renuka Pudi Limgala, Chidima Ioanou, Matthew Plassmeyer, Mark Ryherd, Lina Kozhaya, Lauren Austin, Cem Abidoglu, Derya Unutmaz, Oral Alpan & Ozlem Goker-Alpan. (2016) Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. PLOS ONE 11:12, pages e0168135.
Crossref
Crossref
Søren Ulrik Sønder, Renuka Pudi Limgala, Margarita M. Ivanova, Chidima Ioanou, Matthew Plassmeyer, Gerald E. Marti, Oral Alpan & Ozlem Goker-Alpan. (2016) Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease. Blood Cells, Molecules, and Diseases 59, pages 8-15.
Crossref
Crossref
Ana Maria Almeida Souza, Thiago Pimentel Muniz & Rafael Maciel Brito. (2014) Study of enzyme replacement therapy for Gaucher Disease: comparative analysis of clinical and laboratory parameters at diagnosis and after two, five and ten years of treatment. Revista Brasileira de Hematologia e Hemoterapia 36:5, pages 345-350.
Crossref
Crossref
Sofie Geens, Philippe Kestelyn & Ilse Claerhout. (2013) Corneal Manifestations and In Vivo Confocal Microscopy of Gaucher Disease. Cornea 32:7, pages e169-e172.
Crossref
Crossref
Márcia Séllos-Moura, Samad Barzegar, Luying Pan, Philip Shi, Susan Oommen, Judith Durant & Juan A. Ruiz. (2011) Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease. Journal of Immunological Methods 373:1-2, pages 45-53.
Crossref
Crossref
Encarna Guillén-Navarro & Rosario Domingo-Jiménez. (2011) Tratamiento enzimático sustitutivo en las enfermedades lisosomales. Anales de Pediatría Continuada 9:2, pages 98-105.
Crossref
Crossref
R. Mark Payne, P. Melanie Pride & Clifford M. Babbey. (2011) Cardiomyopathy of Friedreich’s Ataxia: Use of Mouse Models to Understand Human Disease and Guide Therapeutic Development. Pediatric Cardiology 32:3, pages 366-378.
Crossref
Crossref
Inna Bendikov-Bar, Idit Ron, Mirella Filocamo & Mia Horowitz. (2011) Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells, Molecules, and Diseases 46:1, pages 4-10.
Crossref
Crossref